Imatinib (Gleevec), a well-known inhibitor of the oncogenic Bcr-abl fusion protein responsible for chronic myelogenous leukemia (CML), has been used to target PDGFR in gastrointestinal stromal tumors KIT positive. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.